CA2594692A1 - Crystalline forms of rosuvastatin calcium salt - Google Patents

Crystalline forms of rosuvastatin calcium salt Download PDF

Info

Publication number
CA2594692A1
CA2594692A1 CA002594692A CA2594692A CA2594692A1 CA 2594692 A1 CA2594692 A1 CA 2594692A1 CA 002594692 A CA002594692 A CA 002594692A CA 2594692 A CA2594692 A CA 2594692A CA 2594692 A1 CA2594692 A1 CA 2594692A1
Authority
CA
Canada
Prior art keywords
hydrates
methylsulfonyl
fluorophenyl
bis
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002594692A
Other languages
English (en)
French (fr)
Inventor
Fritz Blatter
Paul Adriaan Van Der Schaaf
Martin Szelagiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2594692A1 publication Critical patent/CA2594692A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002594692A 2005-01-31 2006-01-23 Crystalline forms of rosuvastatin calcium salt Abandoned CA2594692A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100598 2005-01-31
EP05100598.1 2005-01-31
PCT/EP2006/050351 WO2006079611A1 (en) 2005-01-31 2006-01-23 Crystalline forms of rosuvastatin calcium salt

Publications (1)

Publication Number Publication Date
CA2594692A1 true CA2594692A1 (en) 2006-08-03

Family

ID=36168368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002594692A Abandoned CA2594692A1 (en) 2005-01-31 2006-01-23 Crystalline forms of rosuvastatin calcium salt

Country Status (5)

Country Link
US (1) US7932387B2 (cg-RX-API-DMAC7.html)
EP (1) EP1844021A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008528542A (cg-RX-API-DMAC7.html)
CA (1) CA2594692A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006079611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
SI2024341T1 (sl) 2006-05-03 2016-04-29 Msn Laboratories Private Limited Novi postopek za statine in njihove farmacevtsko sprejemljive soli
EP1948618A1 (en) 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) * 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
HRP20140723T1 (hr) * 2009-01-14 2014-10-24 Krka, Tovarna Zdravil, D.D., Novo Mesto Postupak za proizvodnju rosuvastatina
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
EP2464344A2 (en) * 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011074016A1 (en) * 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
US9249108B2 (en) 2010-11-22 2016-02-02 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
CA2832343A1 (en) 2011-04-18 2012-10-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法
PL3445751T3 (pl) 2016-04-18 2023-09-18 Morepen Laboratories Limited Nowa polimorficzna postać krystalicznej rozuwastatyny wapniowej i nowe procesy otrzymywania krystalicznej i amorficznej rozuwastatyny wapniowej
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004072040A1 (en) 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
WO2005037787A1 (en) 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
EP1711493A2 (en) 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
WO2006035277A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
EP1948618A1 (en) 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium

Also Published As

Publication number Publication date
US7932387B2 (en) 2011-04-26
US20080194604A1 (en) 2008-08-14
WO2006079611A1 (en) 2006-08-03
EP1844021A1 (en) 2007-10-17
JP2008528542A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
US7932387B2 (en) Crystalline forms of rosuvastatin calcium salt
CN100430405C (zh) 制备他汀类的钙盐形式的方法
WO2007099561A1 (en) Process for preparing rosuvastatin calcium
CA2427255A1 (en) Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
CA2877030A1 (en) Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
WO2005051921A1 (en) Crystalline ammonium salts of rosuvastatin
KR20110128194A (ko) 의약제로서의 로수바스타틴 락톨의 용도
EP3080141A1 (en) Solid form of abiraterone acetate
US9249108B2 (en) Multicomponent system of rosuvastatin calcium salt and sorbitol
JP2008528542A5 (cg-RX-API-DMAC7.html)
US8841316B2 (en) Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
JP2008526897A (ja) ロスバスタチンのジアステレオマー精製
JP3539926B2 (ja) 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法
WO2013124791A1 (en) Solid form of bosentan
US20140155371A1 (en) Multicomponent crystalline system of ezetimibe and proline
EP2788344A1 (en) Multicomponent crystalline system of voriconazole with fumaric acid
CN103570626A (zh) 二氢嘧啶衍生物的盐
EP2334667A1 (en) A process for preparation of rosuvastatin acetonide calcium
JP2013500250A (ja) 結晶型iのロスバスタチン亜鉛塩
AU2005245628A1 (en) Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
CN105073713A (zh) 药学上可接受的匹伐他汀胺盐
JP2013542977A (ja) 結晶性の薬学上活性な成分
CN1875008A (zh) 制备罗素他汀钙的方法
JPH11505508A (ja) ピリミジノン誘導体
KR20120101399A (ko) 피리미딘­5­일 아세트산 유도체의 콜린염의 다형체를 제조하는 방법

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150910